Norma Tecnica en Tbc

7/25/2019 Norma Tecnica en Tbc

1/5

ACTUALIZACIN DEL SUB NUMERAL 7. TRATAMIENTO DE LATUBERCULOSIS DE LA NTS N 041-MINSA/DGSP-V.01 NORMA

TCNICA DE SALUD PARA EL CONTROL DE LA TUBERCULOSISAPROBADA POR R.M. N !"!-#00$/MINSA

E% &'()(*+( ,(*+ +%23 (% ) *('% 7. TRATAMIENTO DE LATUBERCULOSIS5 ,( %) DISPOSICIONES ESPEC6ICAS5 ,( % NTS N041-MINSA/DGSP-V.01 N' T8*2 ,( S%, &' (% *+'% ,( ,( %T('%)2) &', &' R.M. N !"!-#00$/MINSA5 9 , %) &+) &'% +%232:* ,(% *(; +('&8+2 ,( % T('%)2) (* (% P('


2/5


3/5

ACTUALIZACIN DEL SUB NUMER AL 7. TRATAMIENTO DE LA TUBERCULOSISDE LA NTS N 041-MINSA/DGSP-V.01 NORMA TCNICA D E SALUD PA RA EL CONTROL D E LA TUB ERCULOSIS

APROBADA POR R.M. N !"!-#00$/MINSA

%) (*(') * &%(* ()+'2+(*+( % + ,( +,) %) (,2(*+) 9 &'+*+)( 2*'((*+ (% '2()= ,( ')5 *,* 9 ('+(. E% +'+2(*+ + -,2*2)+', , %=' % &+(*2% '(2:* ,( '()2)+(*2 (,2(*+) 9 %

+'*)2)2:* ,( TB '()2)+(*+( *+22:+2) %) +';,'() ,( )%, 9 % *2,,5&' % ( )( *)+2+9( (* * ='@( %+ *+' % )%, & %) ')) ,(+'+2(*+.

. T2(& )22(*+( ,( +'+2(*+5 * * **2&'(*+;( ,( '(>,).

. R(2*() ,@(')) >*2),. A,2*2)+'2:* ,( (,2(*+) (* DIRECTAMENTE OBSERVADO &' (%

&(')*% ,( )%, ,'*+( % 2*=()+ ,(% (,2(*+ 9 ( ='*+2( % ,('(*2 9

* (%% (% &%22(*+ ,( % +('&2.

7.#. MEDICAMENTOS ANTITUBERCULOSIS

7.#.1. MEDICAMENTOS ANTITUBERCULOSIS DE PRIMERA L6NEAL) (,2(*+) ,( &'2(' %>*( )( +2%23* (* &2(*+() *(@)5 '(>,) 9*,*) '(&(',)5 )* %+(*+( (2() 9 ,( (* +%('*2 &' (% &2(*+(.

C,' N 1. M(,2(*+) A*+2+('%)2) ,( P'2(' L>*( - C'+('>)+2)%>*2 '%:=2)

ACTIVIDAD

CONTRAMEDICAMENTO ABSORCIN METABOLISMO ECRECINM9+('2+('%)2)

B+('22, *&,(' ()+('2%23*+(

R2&22*? R

A)'2:*'(+',, &'%2(*+)

H(&+2 M9' &'+( (*(().#0-!0K &''2F:*.

I)*232,?H

A%+(*+( M(;' )'2:*(* 9*)

H(&+2 R(*%+('22,

P2'32*2,?Z

B+('22, (*(,2 2,

E(+ ,(%2(*+) (*

2,2)&*22%2,,() >*2.

H(&+2 70K &' '2F:*.

E++%?E

B+('2)++2?&'%((*+(

+('22, %+),)2)

E(+ ,(%2(*+) (*

2,2)&*22%2,,() >*2.

R(*% 9 (&+2 "0K &' '2F:*.

E)+'(&+22*?S

B+('22, (*&%2:*(J+'(%%'

P'(*+('% D2)+'22:* &%2 0-$0K &''2F:* 9

&((F*+2,, &'

2%2)

(* +(;2,) 9%>2,) '&'%()

#


4/5



S2=%) 22%() ,( %) (,2(*+) (* (% PER 9 '((*,,) &' % OMS.

A. RIAMPICINA ?R

E) +('22, *+' 2%) (J+' ( 2*+'(%%'(). S( )'( '&2,(*+( * @(32*=('2,5 &(' &(,( )(' ,(', ,2)2*2, &' %2(*+) 9 '2) (* ='). S

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

B. ISONIACIDA ?H

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

C. PIRAZINAMIDA ?ZE;('( ((+ +('22, )'( % &%2:* +('2* )(2,'2, ,'2(*+(*+(*2, ,(*+' ,( %) ':=) (* (% 2(*+( 2, ,( %) ) )()).P(,( )(' +, * )2* %2(*+). L (J&)22:* % )% ,(( )(' &',(*+( &'(@2+' ') +*(.A+'@2() (% SNC %='*, *(*+'2:* )22%' % )8'2. L OMS '(2(*, ) )(* =()+*+() * TB. EL '2()= ,( 2&(''2(2 ()+ 2*'((*+, (* &2(*+() *2*)22(*2 '(*% &' % ( '(2('( ,( ;)+( ,( ,)2).

D. ETAMBUTOL ?E

B+('2)++2 ,)2) ,( #0 =//,. S *2:* (* (% ()( ,( +'+2(*+ ()&'+(=(' *+' (% ,()''%% ,( '()2)+(*2 R2&22* (* ,*,( % '()2)+(*2 I)*232, &(,( ()+' &'()(*+(. S( &(,( 2*=('2' * )2* %2(*+). L) *+22,)2*+('2('(* * % ,'=. S( ()&(' * *(*+'2:* &2 ,( #-$ =/%. S ) ()

)(=' (* %2(' () ,(% ('3 9 (* % %+*2.D. ESTREPTOMICINA ?S

E) (% *(. C* +2@2,, +('22,*,(*+%(*+( (* &%2:* (J+'(%%'5 +2,) '&'%(). C* &'(&(*(+'2:* (* ''(' (+(*(%2.

!


5/5



I*+('2('( * % )>*+()2) &'+(25 )( 2* * %) '2)) M9+('2*),(+('2**, )> ) % %(+' ,(% :,2= =(*8+2.S (J'(2:* () &' @> '(*% ?0 $0K 9 * &((F *+2,, &' % 2%2). P' ()+(+2@ ,(( ;)+')( % ,)2) (* '(%2:* % *2:* '(*%5 ,(2(*, +(*('&'(2*() (* &2(*+() 9'() &'+,'() ,( 2*)22(*2 '(*%. O+' ((+

%+('% 2&'+*+( 9 ( ,(( )(' *2+'(, () % ++J22,,.D(( *)2,('')( ) ) %+('*+2@ E++%5 *, ()+( &(, ,()''%%'&+(*2%(*+( N('2+2) &+2Q +28* (* )) * ,()+', )(*)22%2,, %(,2(*+.

E. PREPARACIONES COMBINADAS

L ESNPCT @'(( (% ) ,( &'(&'2*() 2*,) ,( ,)2) 2;) ,( INH-RMP

&' (@2+' % &8',2, ,( * ,( %) ,) ,'=) ( *)+2+9(* (% NCLEO BSICO ,(%T'+2(*+ ,( % TB SENSIBLE.

7.#.#. MEDICAMENTOS ANTITUBERCULOSIS DE SEGUNDAL6NEAL) (,2(*+) ,( )(=*, %>*( )( +2%23* (* &2(*+() *+('%)2) '()2)+(*+( *+22:+2). E)+) ') )(%(* +(*(' ((+) ) +:J2)5 9) 2:* +('&8+2'(2('( ,( ) &'%*=, &' %*3' % '2:*. E* (%

) ,(M%+2,'=''()2)+(*2 )( '(2(*, ,( % (*) 1" ()() ,(+'+2(*+.CLASIICACIN DE LOS MEDICAMENTOS PARA ELMANEO DE LATUBERCULOSISG'& 1 A%=*) ') '%() ,( &'2(' %>*(5 I)*22,5 R2&22*5

P2'32*2, 9 E++%5 &(,(* +2%23')( (* (% *(; ,( %+('%)2) %+2,'='()2)+(*+(. S2 % P'( ,( S(*)22%2,, ?PS 2*,2 ( * ())(*)2%( E++% 9/P2'32*2,5 ,((* )(' *)2,(',) (* (% *(@ ()(5 9 ()* (;' +%(',)( %) (,2(*+) ,( )(=*, %>*(.G'& # I*%9 (,2(*+) 2*9(+%() ?*22*5

A22*5 E)+'(&+22*5C&'(22*Q )2 (% &2(*+( () )(*)2%( )( '(2(*,()+'(&+22* &'2('&2:*. S2 () '()2)+(*+( ()+'(&+22*5 % )(=*, &2:* ()*22*. S2 % (&() '()2)+(*+( +*+ ()+'(&+22* *22*5(*+*() % (%(2:* ()C&'(22*. E* &'()(*2 ,( '()2)+(*2 *22*5

E)+'(&+22* 9C&'(22* )( ,(2,2' (* (% CERI 9 CERN (% ) 9 )(,( A22* C&'(22*.L C&'(22* 9 A22* )* ,( ) '()+'2*=2,5 +'23,)UNICAMENTE &' %UT-TB MDR.G'& ! C&'(*,( %) 2*%*) ?(* ',(* ,()(*,(*+(

,( &+(*2MJ2%J2*5 L(@%J2*5 C2&'%J2*5 ( )* ') ,()(=*, %>*( '%()9 +('22,). S( ,(( 2*%2' * 2*%* (* , '8=2(* ,(+'+2(*+ &' MDR.

4



C,' N #. M(,2(*+) A*+2+('%)2) ,( S(=*, L>*( &' (% *(;T('%)2) R()2)+(*+( D'=)

C'+('>)+2) %>*2 '%:=2).

ACTIVIDADMEDICAMENTO CONTRA TB ABSORCIN METABOLISMO ECRECIN

*22*?

B+('22, P'(*+('%

A22*?A

B+('22, P'(*+('% D2)+'22:* &%2(* +(;2,) 9 %>2,) R(*%

'&'%()C&'(22*?C

B+('22, P'(*+('%

E)+'(&+22* ?S B+('22, P'(*+('%L(@%J2* ?LJ B+('22, A,2*2)+'' # ') ,()&8) R(*% R(*%

(* ) ,( (' 2*=('2,%2(*+) %+()5 *+22,)5 +' (,22:* *+(*2(*,(5 M=5 C5 Z*5 @2+2*)5,2,*:)2,5 )'%+.

H(&+2A%+(*+(B+('22,

S )'2:* () )2 ++% +')% ,2*2)+'2:* '% 9 * )(@( (+, &' % 2*=()+ ,(%2(*+) 2*%2,) %+().

B2%2) 9 R(*%MJ2%J2*?MJ

C2&'%J2*?CJ

B+('22, E(+ ,( %2(*+) (* H(&+2 "0K R(*%2,2) &*22 %2,, () >*2.S2* ('= ) )'2:* )('(,( (* &'()(*2 ,(%2(*+) * %+ *+(*2,,( %2 ?%+() 9 +')2*().

E+2*2, ?E+ D82%(*+(+( '22,

A)'2:* (*+('% H(&+2 R(*%

A2, &'2*)%2>%2 ?PAS

B+('2)++2 $0-$K )'2:* '% H(&+2 R(*%

C2%)('2*?C)

B+('2)++2 O'%. M9 (* R(*%&(*(+ '2:* (* (%S2)+( N('@2)C(*+'%

C%322*( ?C B+('2)++2 4 % $#K ,( % ,)2) '% H(&+2 R(*%

AJ22%2*/2,%@%*2?AJ/C%@

B+('22, 2*@2+'

G)+'2 9 (*+('% H(&+2 R(*%

C%'2+'22* ?C%' P'%( G)+'25 %(@( %+('2:* *%) %2(*+)

H(&+2 H(&+2+( '2)++2((+ ,()2*('=2 * E

E+ +% ? E B+ ('2 )++ 25& G) +' 2 * (+ , &'%2(*+)

H(&+2 R(*%'%(+( '22, ,)2) %+)

I2&(*(/2%)+2*?I&/C%*

B+('22, 2*@2+'

P'(*+('% H(&+2 R(*%

I)*22, ? ,)2)%+) ?H

B+('22,&+(*+ ( (*(&) )(*)2%()

G)+'2 9 (*+('% H(&+2 H(&+2

E*+('% 9 &'(*+('% )2&%(+

H(&+2 H(&+2 9L2*(3%2, ?LZD B+('22, (*(&)MDR/DR

'(*%

M('&(*( ?M& B+('22, 2*P'(*+('% &%(+ H(&+2 H(&+2 9@2+' '(*%

P2'32*2, ?Z B+('22, E*+('% 9 =)+'2 H(&+2 H(&+2 92*+'(%%' '(*%

S* D'=) ,( P'2(' L>*( &(' )2 % PS 2*,2 ( )* )(*)2%() &(,(* )(' ),) (* (% *(; ,( TB MDR. N )( (*(*+' (* (% P(+2+'2 N2*% *2 ,( M(,2(*+) E)(*2%()5 )2* ('= % ESN PCT &(,(=()+2*' *+( DIGEMID % +'232:* &' % ,2)22:* )(=

Norma Tecnica en Tbc

Documents

Transcript of Norma Tecnica en Tbc